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Guobao Wang, MD,‡ Nan Jia, PhD, MD,‡ Meng Dai, PhD, MD,§ and Xiaoyan Bai, PhD, MD‡
Introduction: Thyroid transcription factor-1 (TTF1) plays a role in
lung adenocarcinoma development. We investigated the significance
of TTF1 in primary lung adenocarcinomas, lymph node metastases,
and malignant pleural effusions (MPEs).
Methods: We studied TTF1 in 175 primary lung adenocarcinomas,
52 lymph node metastases, and 46 MPE using microarray-based
fluorescence in situ hybridization, immunohistochemistry, and mes-
senger RNA (mRNA) in situ hybridization. Real-time reverse tran-
scription polymerase chain reaction was used to investigate corre-
lations between TTF1 amplification and mRNA expression.
Correlations between clinicopathologic characteristics, TTF1 ampli-
fication, TTF1 expressions, overall survival, and prognosis were
analyzed.
Results: TTF1 was amplified in 7% of primary lung adenocarcino-
mas, 4% of lymph node metastases, and 4% of MPE. TTF1 ampli-
fication in lung adenocarcinomas was associated with pathologic
subtypes (p  0.029). Patients with positive TTF1 protein and
mRNA expressions had improved overall survival if TTF1 was
unamplified compared with those with TTF1 amplification (p 
0.068). A multivariate model did not show patients with positive
TTF1 expressions tended to have better prognoses if TTF1 was
unamplified compared with those with TTF1 amplification (p 
0.068). Survival time was longer for patients with TTF1 expressions
in both primary lung tissues (p  0.001) and MPE (p  0.045). A
multivariate model confirmed the prognostic value of TTF1 expres-
sions in lung adenocarcinoma (p  0.001). A multivariate model
confirmed the prognostic value of TTF1 experssions in lung adeno-
carcinoma tissues (p  0.001) while not in MPE (p  0.058). TTF1
mRNA level was higher in cases with TTF1 amplification compared
with those without TTF1 amplification.
Conclusions: Patients with lung adenocarcinoma without TTF1
amplification tend to have better prognoses than those with TTF1
amplification in cases with positive TTF1 expressions. Positive
TTF1 expressions in lung adenocarcinoma tissues are favorable
prognostic parameters in patients with lung adenocarcinoma.
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Lung cancer is the leading cause of cancer death in theworld. Current therapies are relatively ineffective, and the
cure rate remains dismally low with the 5-year survival rate
of approximately 15%. Approximately 15% of patients with
lung cancer have malignant pleural effusions (MPEs) at the
time of initial diagnosis and an additional 50% develop a
pleural effusion later in the course of their disease. Patients
with MPE have a shorter life expectancy and are difficult to
manage clinically.
Thyroid transcription factor-1 (TTF1), also known
as Nkx2.1, is a 38-kDa transcription factor normally ex-
pressed in the thyroid, lung, and brain. Guazzi et al.1 using
in situ hybridization mapped TTF1 in the mouse to chro-
mosome 12C1-C3 and in humans to chromosome 14q13.
Previous studies have shown that TTF1 is an important
lineage-specific marker for lung adenocarcinoma, and
TTF1 gene amplification has been detected in lung adeno-
carcinomas.2,3
Although studies have shown correlations between
TTF1 amplification and protein expression in primary lung
cancer,2 correlation of TTF1 amplification with TTF1 protein
and messenger RNA (mRNA) expressions in lung adenocar-
cinoma lymph node metastases and MPEs have not been
established.
In this study, we investigated the relationships between
TTF1 gene amplification and TTF1 protein and mRNA ex-
pressions in primary lung adenocarcinomas, corresponding
lymph node metastases, and MPE from patients with lung
adenocarcinoma. We also looked for correlations between
TTF1 amplification and clinical pathologic characteristics and
the patient overall survival and prognosis.
*Department of Emergency, †Department of Pathology, ‡Guangdong Pro-
vincial Institute of Nephrology, and §Health Management Center, Nan-
fang Hospital, Southern Medical University, Guangzhou, Guangdong,
People’s Republic of China.
Disclosure: The authors declare no conflicts of interest.
The first two authors contributed equally to this study.
Address for correspondence: Xiaoyan Bai, MD, PhD, Guangdong Provincial
Institute of Nephrology, Nanfang Hospital, Southern Medical University,
1838 Guangzhou North Road, Guangzhou, Guangdong 510515, People’s
Republic of China. E-mail: xiaoyanbai@fimmu.com, or Meng Dai, PhD,
MD, Health Management Center, Nanfang Hospital, Southern Medical
University, Guangzhou North Road, Guangzhou, Guangdong, P.R.
China, 510515. E-mail: dm42298@21cn.com
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/12/0701-0076
Journal of Thoracic Oncology • Volume 7, Number 1, January 201276
MATERIALS AND METHODS
Patients’ Parameters
One hundred seventy-five patients with lung adenocar-
cinoma treated in Nanfang Hospital in Guangzhou, China,
from 2000 to 2006 were selected for this study. According to
the International Association for the Study of Lung Cancer/
American Thoracic Society/European Respiratory Society
pathologic classification,4 the predominant subtypes are pap-
illary/bronchioalveolar, acinar, solid, and invasive mucinous
adenocarcinoma. In addition, lung cancer is classified as well,
moderately, or poorly differentiated tumors. The inclusion
criteria for this study are as follows: (1) papillary/bronchio-
alveolar and invasive mucinous subtype; (2) patients had no
radiotherapy or chemotherapy; (3) patient follow-up data of 6
months or greater were available from the Health Manage-
ment Center of Nanfang Hospital; and (4) an adequate par-
affin block was available for analysis. The clinical pathologic
characteristics, defined by World Health Organization crite-
ria,4–6 included patients’ gender, smoking status, tumor lo-
cation, pathologic subtype, tumor differentiation, lymph node
metastasis, tumor size, and stage (Table 1).
Specimens from these patients were obtained from the
Department of Pathology and the Department of Thoracic
Surgery in Nanfang Hospital. The specimens included 175
paraffin-embedded primary tumor samples, 52 corresponding
lymph node metastases, and 46 MPEs. Fourteen snap-frozen
fresh tumor samples and matched normal lung tissues from
the primary tumor were also available for the study. Normal
lung tissues at least 5 cm from the tumor obtained from two
of the patients served as normal controls.
Written informed consent was obtained from all pa-
tients according to the protocols of the Southern Medical
University Ethnics Committee.
Nuclei Microarray Construction
Methods for constructing nuclei microarrays (NMAs)
and extraction of nuclei from paraffin-embedded tissue
blocks have been described elsewhere.7 Briefly, a blank cell
microarray paraffin block was made in a 10  10 matrix
using a manual arrayer (Beecher Instruments, Sun Prairie,
WI, MTA-1). Twenty-micrometer-thick sections were cut
from the paraffin block and placed on a glass slide as a mold
for holding nuclei suspensions. Nuclei were extracted from
paraffin-embedded tissues and MPE samples. During the
process of nuclei extraction, tissue debris was separated from
the nuclei and removed. This ensured a clear background in
fluorescence in situ hybridization (FISH) testing.
For each tissue specimen, four tissue cores were col-
lected for nuclei extractions. Cell density was adjusted to 1
104 cells/l with phosphate buffered saline (PBS, pH 7.4).
For MPE samples, cells from 50 ml of MPE were fixed with
10% formalin for 10 minutes followed by fixation in freshly
prepared methanol-glacial acetic acid (3:1), spun, and resus-
pended in 50 l of distilled water. From each sample, 10 l
nuclei suspensions were put into three wells of the paraffin
mold. Representative images of an hematoxylin and eosin
(H&E)-stained NMA slide and a diamidinophenyl-indole-
stained nuclei disk are shown in Figure 1.
NMA Fluorescence In Situ Hybridization
The NMA slides were dried in a 65°C oven for 1 hour,
fixed with methanol-glacial acetic acid (3:1) for 1 hour. After
air drying, slides were placed in citrate buffer (pH 6.0) and
incubated for 10 minutes in a microwave oven, then trans-
ferred to freshly prepared 0.4% pepsin solution (0.16 g
pepsin, 2850 U/mg solid, in 40 ml of 0.9% sodium chloride,
pH 1.5) and dehydrated through a series of graded ethanol.
Ten microliters of probe solution as recommended by the
manufacturer was applied to the slide, protected with a
coverslip, and sealed with a continuous bead of rubber ce-
ment. Slides were processed with a PTC-200 polymerase
chain reaction (PCR) Thermo Cycler (BIO-RAD, Hercules,
CA) programmed with a melt temperature of 82°C for 10
minutes and hybridization temperature of 37°C for 16 hours.
After hybridization, the coverslip was removed and the sam-
ples were washed sequentially as described previously.8 The
slides were counterstained with diamidinophenyl-indole.
FISH analysis was performed using a bacterial artificial
chromosome (BAC) probe containing NKX2–1 (Empire
Genomics, Buffalo, NY) on NMA slides. BAC clone RP11–
76M21 conjugated to 5-ROX-dUTP (red signal) was used as
the NKX2–1 probe, and BAC clone Chr14 control conjugated
to 5-fluorescein-dUTP (green signal) was used as the refer-
ence probe (Empire Genomics). The integrity and purity of
all probes were verified by hybridization to metaphase








Male 110 (63%) 25 (54%)
Female 65 (37%) 21 (46%)
Smoking status
Nonsmoker 70 (40%) 23 (50%)
Smoker 105 (60%) 23 (50%)
Tumor location
Central 60 (34%) 34 (74%)
Peripheral 115 (66%) 12 (26%)
Pathologic subtype
Papillary/BAC 165 (94%) 37 (80%)
Mucinous 10 (6%) 9 (20%)
Differentiation
Well 75 (43%) 28 (61%)
Moderately and poorly 100 (57%) 18 (38%)
LN metastasis
Yes 92 (53%) 41 (89%)
No 83 (47%) 5 (11%)
Tumor size
3 cm 39 (22%) 28 (50%)
3 cm 136 (78%) 28 (50%)
Stage
I–II 84 (48%) 0
III–IV 91 (52%) 46 (100%)
MPE, malignant pleural effusion; LN, lymph node; BAC, bronchioalveolar carcinoma.
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spreads of normal peripheral lymphocytes. The samples were
analyzed under a 63 oil immersion objective using a Nikon
ECLIPSE TE2000-S inverted fluorescence microscope with
appropriate filters. One hundred nontouching nuclei with
intact periphery and clear positive signal were observed from
each specimen. Nuclei with more than three red signals were
determined as having amplification of the NKX2-1 gene.
Quantitative Real-Time Reverse Transcription
PCR and Reverse Transcription PCR
We performed SYBR green real-time quantitative PCR
analysis on the 14 microdissected frozen lung samples. Briefly,
4-m-thick frozen sections of the tumors and paired adjacent
normal lung were cut and stained with H&E and subsequently
subjected to laser capture microdissection (Cut, SL-Microtest,
Glattsbrugg, Switzerland). Total RNA from microdissected
snap-frozen tissues was extracted using TRIzol reagent. Then
first strand cDNA was synthesized using 2 g of total RNA
treated with M-MLV reverse transcription (RT, Promega, Mad-
ison, Wisconsin) according to the manufacturer’s instructions.
Quantitative RT-PCR analysis was performed in triplicate with
a Power PCR SYBR Green Master Mix reagent (Applied Bio-
systems, Carlsbad, CA) using the ABI PRISM 7500 FAST
Real-TIME PCR System (Applied Biosystems) with results
normalized to -actin (ACTB) expression. The CT was used
to calculate relative expression of the TTF1 gene. The entire
coding region was amplified by PCR in 30 l reactions contain-
ing 1 l cDNA (200–500 ng/l), 1 l primers (10 mol/L), 0.5
l 10 mM deoxynucleotide triphosphate, 3 l 10 PCR buffer
(with MgCl2), and 0.2 l TaqDNA polymerase (5 U/l) (Bio-
engineering Co., Ltd., Shanghai, China). The primers used for
ACTB were forward 5-TGGCCACTTCCGGGGTACTGT-3
and reverse 5-CAGGTGAGCCCCGGCCTTCT-3. The primers
used for TTF1 were forward 5-AGGACACCATGAGGAA-
CAGC-3 and reverse 5-GCCATGTTCTTGCTCACGTC-3.
Immunohistochemistry and In Situ
Hybridization on Tissue Microarray and
MPE Slides
A tissue microarray (TMA) was constructed from the 175
paraffin-embedded blocks according to the procedure described
previously.9 Four tissue cores selected from the defined regions
of each sample were used to construct a 30  30 matrix
microarray. In the final row of the microarray, 16 cores were
used as indicators of sample locations. After centrifugation of
the 20 to 100 ml MPE at 2000 rpm for 5 minutes, cell clumps
were wrapped with filter paper, fixed with 10% formalin for 10
minutes at room temperature, and embedded in paraffin. The
percentage of malignant cells in the MPE-paraffin block was
greater than 95. Several 3-m-thick sections were cut from the
TMA and MPE blocks. One slide was stained with H&E and
used for morphological observations. The remaining sections
were used for immunohistochemistry (IHC) and in situ hybrid-
ization (ISH) labeling.
Immunohistochemistry
TMA andMPE slides were stained with mouse antihuman
TTF1 monoclonal antibody (TTF1, clone 8G7G3/1; Dako,
Carpinteria, CA) using the standard streptavidin-biotin complex
method. Sections were deparaffinized with xylene, rehydrated
with a graded series of ethanol, and rinsed in PBS. Deparaf-
finized sections were incubated in citrate buffer (pH 6.0) for 10
minutes at 120°C in a pressure cooker. The sections were cooled
to room temperature and treated with 3% hydrogen peroxide to
inactivate endogenous peroxidase. The sections were blocked
with normal nonimmune serum for 30 minutes at 37°C and then
incubated with TTF1 antibody (1:200) at 4°C for 12 hours.
Sections were then washed three times in PBS and treated with
biotin-conjugated secondary antibody (ZhongShan Golden
Bridge Biotechnology Co., Ltd., Beijing, China) for 30 minutes
at room temperature. Antibody localization was enhanced using
a peroxidase reaction with 3, 3-diaminobenzidine tetrahydro-
chloride (DAB, ZhongShan Golden Bridge Biotechnology Co.,
Ltd., Beijing, China).
mRNA In Situ Hybridization
The specific probe was used to detect TTF1 mRNA
expression in TMA and MPE samples. TTF1 mRNA-specific
oligonucleotide probe was designed by Bioasia Co. Ltd., Shang-
hai, China. The sequence of the probe was 5-GCCGACAGG-
TACTTCTGTTGCTTGAAGCGT-3. The probe was labeled
by digoxin on both the 3- and 5 end. TMA and MPE sections
were deparaffinized, rehydrated, rinsed in PBS, and digested
with pepsin at 37°C for 20 minutes. Slides were hybridized with
FIGURE 1. Thyroid transcription factor-1 (TTF1) gene amplifi-
cation in primary lung adenocarcinoma, lymph node metasta-
sis, and malignant pleural effusions detected with nuclei
microarray fluorescence in situ hybridization (NMA-FISH). A,
Overview of a NMA slide (hematoxylin and eosin [H&E]). B,
One NMA disk stained by diamidinophenyl-indole (DAPI,
original magnification, 200). C, TTF1 gene amplification in
primary lung adenocarcinoma (63 oil). D, TTF1 gene amplifi-
cation in lymph node metastasis (63 oil). E, TTF1 gene amplifica-
tion in MPEs (63 oil). Red signals represent amplification of the
NKX2-1 probe and green signals represent a chromosome 14 ref-
erence probe. Nuclei are stained in blue with DAPI.
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the riboprobe at 38°C for 16 hours. The hybridization samples
were washed sequentially in 2 sodium chloride and sodium
citrate (SSC) at 37°C for 5 minutes and then in 0.5 SSC at
37°C for 30 minutes. Slides were treated with 3% hydrogen
peroxide to inactivate endogenous peroxidase. Then pepsin di-
luted with 3% citric acid was used to expose mRNA fragments.
Sections were hybridized with a probe diluted with hybridization
solution to a final concentration of 3 g/ml for 16 hours at 38°C.
The hybridization samples were washed sequentially three times
in 2 SSC for 5 minutes at 37°C, twice in 0.5 SSC for 5
minutes at 37°C, and once in 0.2 SSC for 15 minutes at 37°C.
The hybridized probe was detected using a Detection W Kit
(Boster Co. Ltd., WuHan, China) according to the manufactur-
er’s instructions. Briefly, slides were incubated with blocking
reagent for 30 minutes at 37°C, then with biotin-labeled sheep
antidigoxigenin for 1 hour at 37°C. The slides were washed
sequentially in 0.5 M PBS at 37°C for 5 minutes. Next the slides
were incubated with streptavidin-biotin complex for 30 minutes
and washed four times in 0.5 M PBS for 5 minutes. Finally, the
slides were incubated with biotin peroxidase for 30 minutes at
37°C and washed four times in 0.5M PBS for 5 minutes. The
peroxidase reaction was enhanced using DAB. Both IHC and
ISH slides were counterstained with hematoxylin and cover-
slipped.
Two cases of normal lung tissue were used as internal
positive controls for both IHC and ISH. PBS or hybridization
solution was used to replace the primary antibody or the
probe and thus served as negative controls.
Analysis of IHC and ISH Slides
The samples were analyzed under a 40 objective lens
using a BX51 light microscope (Olympus, Germany). Twenty
fields were randomly selected within four randomly chosen
representative tissue cores of a specimen on the TMA. In
total, 200 tumor cells were observed. Those with dark brown
particles in the nuclei or the cytoplasm were regarded as
positive protein or mRNA expressions. TTF1 IHC and ISH
staining were recorded as no expression (absent staining 
0), low expression (30% of tumor cells with weak staining
intensity  1), or high expression (30% of tumor cells with
strong staining intensity 2). No expression was regarded as
negative and low or high expression as positive.
Western Blotting for MPE Samples
Cells were washed three times with cold PBS and lysed
on ice in radio-immunoprecipitation assay buffer (1PBS,
1% BP40, 0.1% sodium dodecyl sulfate, 5 mM ethylenedi-
aminetetraacetic acid, 0.5% sodium deoxycholate, and 1 mM
sodium orthovanadate) with protease inhibitors. The protein
lysates were resolved on a 10% sodium dodecyl sulfate
polyacrylamide gel, electrotransferred to a nitrocellulose
membrane (Invitrogen, Carlsbad, CA), and blocked with 5%
nonfat dry milk in Tris-buffered saline, pH 7.5 (100 mM
NaCl, 50 mM Tris and 0.1% Tween-20). Membranes were
probed with mouse antihuman TTF1 monoclonal antibody
(clone 8G7G3/1; 1: 2000, Abcam, Cambridge, MA) and
rabbit antihuman GAPDH polyclonal antibody (1: 2000,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at 4°C
overnight. The secondary antibody horseradish peroxidase-
labeled antimouse or antirabbit IgG antibody (ZhongShan
Golden Bridge Biotechnology Co., Ltd., Beijing, China) were
used at 1:5000 dilution for 1 hour at room temperature. The
supersignal-enhanced chemoluminescence (Pierce Biotech-
nology, Inc., Rockford, IL) substrate was applied to the
probed membrane and exposed for 10 minutes before the
protein bands were visualized and scanned using an Alpha-
EaseFC Analysis tool (Alpha Innotech, Santa Clara, CA).
Statistical Analysis
Clinicopathologic correlations between TTF1 protein
and mRNA expressions and amplification subgroups were
analyzed using two-sided Fisher’s exact test. The relation-
ships between TTF1 amplification and protein and mRNA
expression status among the primary tumor, lymph node
metastasis, and MPE were analyzed using the McNemar test
for nonparametric nominal data. Overall patient survival was
calculated from the time of surgery to the time of death or to the
time of last follow-up, at which point the data were censored.
Overall survival curves were generated using the Kaplan-Meier
method, and the log-rank test was used to evaluate the differ-
ences between expression and amplification subgroups. The
independent prognostic significance of the TTF1 expression and
amplification status was determined using the Cox Proportional
hazards model for multivariate analysis. SPSS 13.0 (SPSS Inc.,
Chicago, IL) was used for all statistical analysis. A p value less
than 0.05 was regarded as statistically significant.
RESULTS
TTF1 Amplification in Primary Lung
Adenocarcinoma, Lymph Node Metastases,
and MPE
The percentage of the cells with an amplified signal
ranged from 9.6 to 28.5%. We identified two categories of
patients with TTF1 protein and mRNA expressions: (1)
patients with TTF1 gene amplification and (2) patients with-
out TTF1 gene amplification. TTF1 gene amplification was
observed in 7% (13/175) of primary lung adenocarcinomas,
4% (2/52) of lymph node metastases, and 4% (2/46) of MPE
(Figure 1). No TTF1 gene amplification was observed in the
normal control lung tissues. TTF1 amplification was more
frequent in papillary/BAC subtype than invasive mucinous
subtype with statistical significance (p  0.029). TTF1 am-
plification and associated clinicopathological characteristics
are summarized in Table 2.
Increased TTF1 mRNA Level in Lung
Adenocarcinomas with TTF1 Gene Amplification
TTF1mRNA expression level was twofold higher in three
snap-frozen fresh tumor tissues (T4, T5, and T6) with TTF1
gene amplification compared with those without amplification
(Figure 2A). Representative TTF1 gene expression in seven pairs
of lung adenocarcinoma tissues and matched normal lung tissues
were detected using PCR, as shown in Figure 2B.
TTF1 Protein and mRNA Expressions in Lung
Adenocarcinoma Tissues and MPE
TTF1 protein and mRNA expressions in lung adenocar-
cinoma tissues were correlated with tumor pathologic subtypes
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(p  0.032), tumor differentiation (p  0.001), lymph node
metastasis (p  0.001), tumor size (p  0.011), and clinical
stage (p  0.016). No significant correlations were observed
with gender, smoking status, or tumor location.
TTF1 protein and mRNA expressions were detected in
5 of the 46 MPE samples. Positive TTF1 protein and mRNA
expressions were correlated with pathologic subtypes (p 
0.044). No correlations were observed between MPE TTF1
protein or mRNA expressions and gender, smoking status,
differentiation, lymph node metastasis, tumor size or loca-
tion, or clinical stage (Figure 3).
Images of the H&E, IHC, ISH, and Western blotting for
TTF1 in MPE samples are shown in Figure 4. Relationships
between TTF1 protein and mRNA expressions and clinico-
pathologic characteristics in lung adenocarcinoma tissues and
MPE are listed in Table 3.
Correlations between TTF1 Amplification and
TTF1 Protein and mRNA Expressions in
Primary Lung Adenocarcinomas, Lymph Node
Metastasis, and MPE
TTF1 gene amplification was correlated with both
TTF1 protein and mRNA expressions in primary lung ade-
nocarcinomas (p  0.001) and lymph node metastases (p 
0.001). TTF1 gene amplification was not correlated with
TTF1 protein and mRNA expressions in MPE (p  0.25), as
listed in Table 4.
Survival Analysis
The median follow-up period for the 175 patients was
44 months (range: 6–104 months). At the time of censoring
the data, the follow-up data of 61 (35%) cases were lost.
There was a trend toward a worse overall survival for patients
with TTF1 protein and mRNA expressions and TTF1 gene
amplification compared with patients with TTF1 protein and
mRNA expressions and without TTF1 amplification (median:
74.3 versus 48.4 months, p  0.068, Figure 5A). A multivar-
iate model did not show that patients with positive TTF1
protein and mRNA expressions and TTF1 amplification
FIGURE 2. Thyroid transcription factor-1 (TTF1) messenger
RNA (mRNA) expression level was twofold higher in lung
adenocarcinomas with TTF1 gene amplification. A, Quantita-
tive real-time polymerase chain reaction (PCR) showed in-
creased TTF1 mRNA expression level in lung adenocarcino-
mas with TTF1 gene amplification compared with normal
lung and lung adenocarcinomas without TTF1 gene amplifi-
cation. B, Representative image of mRNA expression level of
seven snap-frozen tumor tissues and matched normal lung
tissues detected by reverse transcriptase (RT)-PCR. T4, T5,
and T6 represented three lung adenocarcinoma tissues with
TTF1 gene amplification.
TABLE 2. TTF1 Amplification and Clinicopathologic





(N  162) p
Gender
Male 11 (85%) 99 (61%) 0.135
Female 2 (15%) 63 (39%)
Smoking status
Nonsmoker 2 (15%) 68 (42%) 0.078
Smoker 11 (85%) 94 (58%)
Tumor location
Central 2 (15%) 60 (37%) 0.142
Peripheral 11 (85%) 102 (63%)
Pathologic subtype
Papillary/BAC 10 (77%) 155 (96%) 0.029
Mucinous 3 (23%) 7 (4%)
Differentiation
Well 3 (23%) 72 (44%) 0.157
Moderately and poorly 10 (77%) 90 (56%)
Lymph node metastasis
Yes 5 (38%) 87 (54%) 0.389
No 8 (62%) 75 (46%)
Tumor size
3 cm 1 (8%) 38 (23%) 0.302
3 cm 12 (92%) 124 (77%)
Stage
I–II 4 (31%) 80 (49%) 0.254
III–IV 9 (69%) 82 (51%)
p values listed are derived from Fisher’s exact test.
TTF1, thyroid transcription factor-1; BAC, bronchioalveolar carcinoma.
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tended to have worse prognoses (OR  3.328, p  0.068)
compared with patients with positive TTF1 protein and
mRNA expressions and without TTF1 amplification. The
overall survival time was longer for patients with positive
TTF1 protein and mRNA expressions, than for patients with
negative TTF1 expressions detected by IHC and ISH in both
primary lung tissues (median: 72.6 versus 42.5 months, p 
0.001, Figure 5B) and MPE (median: 72.6 versus 43.9
months, p  0.045, Figure 5C). A multivariate model con-
firmed the prognostic value of positive TTF1 expressions in
lung adenocarcinoma tissues (OR  2.967, p  0.001),
whereas it failed to show a significant prognostic effect of
TTF1 expressions in MPE samples (OR 2.769, p 0.058).
DISCUSSION
TTF1 is normally expressed in the terminal respiratory
unit. Its presence is an indicator of retained differentiation
and a less aggressive phenotype, predicting a good prognosis
for patients with lung adenocarcinoma.
With the discovery of TTF1 gene amplification on 14q
by CGH or SNP arrays,3,10,11 several research groups have
shown TTF1 gene amplification in paraffin-embedded pri-
mary lung adenocarcinomas using TMA-based FISH.2,12–14
There is a trend of longer overall survival in patients with
TTF1 expression but no TTF1 gene amplification compared
with those with no TTF1 expression or TTF1 expression with
TTF1 gene amplification. The phenomenon of TTF1 ampli-
fication in primary lung adenocarcinomas led us to investi-
gate TTF1 gene amplification and expression status in lymph
node metastases and MPEs.
It is revealed in this study that TTF1 gene is amplified
in 7% of primary lung adenocarcinomas, 2% of lymph node
metastases, and 2% of MPE. TTF1 gene amplification is
correlated with the papillary/BAC pathological subtype, in-
dicating a role of TTF1 gene amplification in lung adenocar-
cinoma subtype classification. We never detected TTF1 am-
plification in all three sites, primary tumor, lymph node
metastasis, and MPE, in the same patient. This may be due to
the limited number of samples with TTF1 amplification
available for this study. On the NMA slide, there were
approximately 500 cells with positive signals in one sample.7
The number of tumor cells with positive signals is sufficient
for the FISH analysis.
Similar to TTF1 protein expression, positive TTF1
mRNA expression in both primary tumors and MPE also
indicates a good prognosis in both primary tumors and MPE.
The expression patterns of TTF1 protein and mRNA in this
cohort of samples are consistent with our previous study.9 In
the primary tumors, positive TTF1 protein and mRNA ex-
pressions are more frequently detected in patients with
papillary/BAC pathologic subtypes and well differentiated
tumors, suggesting a role of TTF1 in subtype classification
and retaining differentiation at both the transcriptional and
translational levels. Positive TTF1 protein and mRNA
expressions are more frequently seen in patients with no
lymph node metastasis, a tumor less than 3 cm, or an early
staged (I-II) tumor, indicating a less important role of
TTF1 in the progression and metastasis of lung cancer.
Microscopically, tumor cells in MPE are either diffusely
scattered or form glandular structures, similar to the mor-
phology of the primary tumor.
We found that TTF1 protein and mRNA expressions
were positive in both the primary tumors and corresponding
lymph node metastases in two patients. TTF1 protein and
mRNA expressions was positive in both the lymph node
metastasis and MPE in one patient. Nevertheless, a paired
analysis failed to show significance due to the limited
sample size. More studies are needed to investigate the
role of TTF1 in lung adenocarcinoma metastasis and the
formation of MPE.
Paired analyses have revealed that TTF1 amplification
is correlated with TTF1 protein and mRNA expressions in the
primary and metastatic foci. Nevertheless, TTF1 amplifica-
tion is not correlated with TTF1 protein and mRNA expres-
FIGURE 3. Thyroid transcription factor-1 (TTF1) protein
and messenger RNA (mRNA) expressions were positive in
papillary subtype of primary lung adenocarcinomas and
lymph node metastases and negative in invasive mucinous
primary lung adenocarcinomas (scale bar: 100m). A, Posi-
tive TTF1 protein expression in papillary lung adenocarci-
noma. B, Positive TTF1 mRNA expression in papillary lung
adenocarcinoma. C, Negative TTF1 protein expression in in-
vasive mucinous lung adenocarcinoma. D, Negative TTF1
mRNA expression in invasive mucinous lung adenocarci-
noma. E, Positive TTF1 protein expression in lymph node
metastasis. F, Positive TTF1 mRNA expression in lymph node
metastasis.
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TABLE 3. TTF1 Expression and Clinicopathologic Characteristics in Lung Adenocarcinoma Tissues
and MPE
Characteristics












(N  41) p
Gender
Male 36 74 0.999 2 23 0.648
Female 21 44 3 18
Smoking status
Nonsmoker 28 43 0.139 1 22 0.346
Smoker 29 75 4 19
Tumor location
Central 18 44 0.503 3 31 0.594
Peripheral 39 74 2 10
Pathologic subtype
Papillary/BAC 57 108 0.032 2 35 0.044
Mucinous 0 10 3 6
Differentiation
Well 43 36 0.001 3 25 0.999
Moderately and poorly 14 82 2 16
LN metastasis
Yes 16 76 0.001 3 38 0.084
No 41 42 2 3
Tumor size
3 cm 6 33 0.011 2 26 0.999
3 cm 51 85 3 25
Stage
I–II 35 49 0.016 0 0 —
III–IV 22 69 5 41
p values listed are derived from Fisher’s exact test.
mRNA, messenger RNA; TTF1, thyroid transcription factor-1; MPE, malignant pleural effusion; LN, lymph node; BAC, bronchioal-
veolar carcinoma.
FIGURE 4. Representative images
of thyroid transcription factor-1
(TTF1) protein and messenger RNA
(mRNA) expressions in the MPE of
patients with lung cancer (scale bar:
100 m). TTF1 expressions were
positive in five cases of MPE (three
invasive mucinous types and two
papillary types). A-1, Hematoxylin
and eosin (H&E); A-2, negative
TTF1 protein; and A-3, mRNA ex-
pressions in papillary lung adenocar-
cinoma. B-1, H&E; B-2, positive
TTF1 protein; and B-3, mRNA ex-
pressions in invasive mucinous lung
adenocarcinoma. C, Representative
TTF1 expressions in MPE detected
by Western blot.
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sions in MPE, indicating a less important role of TTF1 in the
MPE formation.
In the 14 fresh tumor samples, TTF1 mRNA level was
twofold higher in cases with TTF1 amplification compared
with those without TTF1 amplification, suggesting that gain
in TTF1 gene copy number is one of the reasons that may lead
to the increased mRNA expression level.
The predictive significance of TTF1 amplification and
TTF1 protein and mRNA expressions could reflect underly-
ing associated pathways that carry their own prognostic




Primary Site (N  175)
TTF1 Protein and mRNA
LN Metastasis (N  52)
TTF1 Protein and mRNA
MPE (N  46) TTF1
Protein and mRNA
  p   p   p
Amplified 5 9 0.001 2 0 0.001 2 0 0.25
Unamplified 52 109 15 35 3 41
p values listed are derived from McNemar test.
mRNA, messenger RNA; TTF1, thyroid transcription factor-1; MPE, malignant pleural effusion; LN, lymph node.
FIGURE 5. Kaplan-Meier estimates of overall survival among patients with lung adenocarcinomas according to thyroid tran-
scription factor-1 (TTF1) expressions and TTF1 amplification. A, There was a trend toward a worse overall survival for patients
with lung adenocarcinoma with positive TTF1 expressions and TTF1 gene amplification compared with patients with TTF1 ex-
pressions and no TTF1 amplification (median: 48.4 versus 74.3 months, p  0.068). B, The overall survival time was longer for
patients with lung adenocarcinoma with positive TTF1 expressions, than for patients with negative TTF1 expressions (median:
72.6 versus 42.5 months, p  0.001). C, The overall survival time was significantly longer for patients with positive TTF1 ex-
pressions in MPE compared with patients with negative TTF1 expressions (median: 72.6 versus 43.9 months, p  0.045).
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implications. As not all tumors expressing high TTF1 levels
harbor gene amplification, TTF1 protein and mRNA expres-
sions in such cases must be driven by mechanisms other than
a gain in TTF1 copy number. Such alternative mechanisms
may include altered transcriptional regulation, mutation, gene
rearrangements, or epigenetic events, which need to be fur-
ther elucidated.
Our study is limited by the small sample size of lymph
node metastases and MPE cases. Additional studies are re-
quired to investigate the potential biological mechanisms
observed in this study.
Several lines of evidence indicate that tumorigenesis is
a multistep process. In lung cancer, the progressive chromo-
somal changes as illustrated in sequence 3p, 9p, 8p, 13q, 17p,
and 5q indicate that the accumulative genetic and epigenetic
changes caused by chromosomal aberrations have led to the
malignant transformation from normal epithelium to invasive
carcinoma.15 These lung carcinogenic processes have shed light
on the functional interactions between genes in different path-
ways. Our results suggest TTF1 gene amplification on 14q might
be another genetic event in the malignant transformation of lung
adenocarcinoma. TTF1 might interact with other genes in the
successive chain events of lung carcinogenesis.
In summary, the investigation of correlations between
TTF1 amplification and expressions and patient overall survival
and prognosis adds evidence to the promising applications of
TTF1 as a predictive clinical biomarker for lung cancer.
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